Here’s what you should know.
1. The approval clears the way for physicians to offer patients the 1-liter colonoscopy prep solution.
2. According to recent studies, most patients rank bowel preparation as one of the biggest barriers to colon care. The majority of complaints centered on the large volume and the unpleasant taste of bowel prep solutions.
3. Salix believes the 1-liter preparation offering could eliminate such barriers.
4. The FDA based its approval on multiple phase 3 clinical trials. In each trial, primary endpoints were met, while Plenvu achieved non-inferior overall bowel cleansing success and an “excellent plus good” level of cleansing. Plenvu is also the only FDA-approved same-day split dosing solution.
5. Salix is a subsidiary of Valeant Pharmaceuticals.
More articles on gastroenterology:
ASC leader to know: Carol Ciluffo of Pinnacle III
Surgical Care Affiliates partners with Massachusetts Avenue Surgery Center — 3 quick facts
University of Maryland Medical System plans $50M investment in medical center with ASC — 4 fast facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
